VBI Vaccines to Present at the Rodman & Renshaw Annual Global Investment Conference
(firmenpresse) - CAMBRIDGE, MASSACHUSETTS -- (Marketwired) -- 09/07/16 -- VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 5:05 PM ET. The event is being held at the Lotte New York Palace Hotel in New York, NY.
During the presentation, Jeff Baxter, VBI''s President and CEO, will provide an and its , and will summarize recent developments in the company''s .
The Rodman & Renshaw 18th Annual Global Investment Conference features more than 300 public and private companies presenting to an audience of over 2,000 attendees. For more information, visit: .
Event Details
About VBI Vaccines Inc.
VBI Vaccines Inc. ("VBI") is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI''s first marketed product is Sci-B-Vac™, a hepatitis B ("HBV") vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI''s eVLP Platform technology allows for the development of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus ("CMV") and glioblastoma multiforme ("GBM"). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Cautionary Statement on Forward-looking Information
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, "forward-looking statements") that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements.
Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company''s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.
VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company''s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Contacts:
VBI Contact
Perri Maduri
Communications Executive
(617) 830-3031 x124
VBI Investor Contact
Nell Beattie
Director, Corporate Development and Investor Relations
(617) 830-3031 x128
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.09.2016 - 06:30 Uhr
Sprache: Deutsch
News-ID 1456579
Anzahl Zeichen: 3446
contact information:
Contact person:
Town:
CAMBRIDGE, MASSACHUSETTS
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"VBI Vaccines to Present at the Rodman & Renshaw Annual Global Investment Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
VBI Vaccines Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
